Endonovo Therapeutics to Present at the 2016 Marcum Microcap Conference in New 
LOS ANGELES, CA -- (Marketwired) -- 05/05/16 --  Endonovo
Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), an
innovative biotechnology company developing a bioelectronic approach
to regenerative medicine, announced today that Endonovo Chairman &
CEO, Alan Collier, will present a company overview at the 2016 Marcum
Microcap Conference on June 2, 2016. The event will be held at the
Grand Hyatt New York on Park Avenue at Grand Central.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is an innovative biotechnology company
developing bioelectronic devices and therapies for regenerative
medicine. Endonovo's Immunotronics(TM) platform is a non-invasive,
non-implantable bioelectronic device for treating/preventing vital
organ failure through the reduction of inflammation, cell death and
the promotion of regeneration. Endonovo's Cytotronics(TM) platform
provides for a method of expanding and manipulating cells using
simulated microgravity and Time-Varying Electromagnetic Fields
(TVEMF) for tissue engineering and cell therapies. The Company's
initial concentration is on the treatment of acute and chronic
inflammatory conditions of the liver using its proprietary
Immunotronics(TM) platform.
Investors: Sign Up for Email Alerts on Endonovo
Safe Harbor Statement
This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
All statements, trends, analysis, and other information contained in
this press release including words such as "anticipate," "believe,"
"plan," "estimate," "expect," "intend," and other similar expressions
of opinion, constitute forward-looking statements. Any such
forward-looking statements involve risks and uncertainties that could
cause actual results to differ materially from any future results
described within the forward-looking statements. Risk factors that
could contribute to such differences include those matters more fully
disclosed in the Company's reports filed with the Securities and
Exchange Commission. The forward-looking information provided herein
represents the Company's estimates as of the date of the press
release, and subsequent events and developments may cause the
Company's estimates to change. The Company specifically disclaims any
obligation to update the forward-looking information in the future.
Therefore, this forward-looking information should not be relied upon
as representing the Company's estimates of its future financial
performance as of any date subsequent to the date of this press
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Vice President of Investor Relations
(800) 701-1223, Ext. 108